United Therapeutics Co. (NASDAQ:UTHR) Shares Bought by Clark Capital Management Group Inc.

Clark Capital Management Group Inc. boosted its stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 3.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 189,341 shares of the biotechnology company's stock after buying an additional 7,053 shares during the quarter. Clark Capital Management Group Inc. owned 0.42% of United Therapeutics worth $66,807,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Cerity Partners LLC increased its stake in United Therapeutics by 30.4% in the 4th quarter. Cerity Partners LLC now owns 11,588 shares of the biotechnology company's stock valued at $4,098,000 after purchasing an additional 2,702 shares in the last quarter. Milestone Asset Management LLC increased its position in shares of United Therapeutics by 56.5% in the fourth quarter. Milestone Asset Management LLC now owns 2,874 shares of the biotechnology company's stock valued at $1,014,000 after buying an additional 1,037 shares in the last quarter. Korea Investment CORP raised its stake in shares of United Therapeutics by 6.2% during the 4th quarter. Korea Investment CORP now owns 39,289 shares of the biotechnology company's stock worth $13,863,000 after buying an additional 2,300 shares during the last quarter. Janney Montgomery Scott LLC boosted its position in shares of United Therapeutics by 9.1% in the 4th quarter. Janney Montgomery Scott LLC now owns 9,427 shares of the biotechnology company's stock worth $3,326,000 after buying an additional 789 shares in the last quarter. Finally, Burney Co. boosted its position in shares of United Therapeutics by 113.3% in the 4th quarter. Burney Co. now owns 23,922 shares of the biotechnology company's stock worth $8,441,000 after buying an additional 12,705 shares in the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have issued reports on UTHR shares. JPMorgan Chase & Co. lowered their price target on shares of United Therapeutics from $355.00 to $350.00 and set an "overweight" rating on the stock in a research report on Thursday, May 1st. Wells Fargo & Company reiterated an "equal weight" rating and set a $314.00 price target (down from $395.00) on shares of United Therapeutics in a report on Friday, April 25th. HC Wainwright reissued a "buy" rating and issued a $425.00 price target on shares of United Therapeutics in a research note on Monday, May 5th. Bank of America upgraded shares of United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 target price for the company in a report on Monday, April 21st. Finally, Morgan Stanley increased their target price on shares of United Therapeutics from $346.00 to $348.00 and gave the stock an "equal weight" rating in a research report on Thursday, May 1st. Four investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, United Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $392.00.

United Therapeutics Price Performance

UTHR traded down $2.86 during trading hours on Tuesday, hitting $307.94. 280,859 shares of the stock were exchanged, compared to its average volume of 439,610. The stock has a market cap of $13.89 billion, a price-to-earnings ratio of 13.52, a price-to-earnings-growth ratio of 0.97 and a beta of 0.58. The stock has a 50-day simple moving average of $300.53 and a 200-day simple moving average of $341.75. United Therapeutics Co. has a 12 month low of $263.56 and a 12 month high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, beating the consensus estimate of $6.29 by $0.34. The business had revenue of $794.40 million during the quarter, compared to analyst estimates of $726.82 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company's quarterly revenue was up 17.2% on a year-over-year basis. During the same period in the previous year, the business posted $6.17 EPS. Sell-side analysts expect that United Therapeutics Co. will post 24.48 EPS for the current year.

Insider Transactions at United Therapeutics

In other news, COO Michael Benkowitz sold 10,000 shares of United Therapeutics stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $360.76, for a total transaction of $3,607,600.00. Following the sale, the chief operating officer now owns 2,577 shares of the company's stock, valued at approximately $929,678.52. The trade was a 79.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction on Thursday, April 3rd. The shares were sold at an average price of $306.18, for a total value of $3,367,980.00. Following the sale, the executive vice president now directly owns 36,781 shares in the company, valued at $11,261,606.58. The trade was a 23.02% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 65,500 shares of company stock worth $20,765,280. 11.90% of the stock is currently owned by company insiders.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.